POTENTIAL USE OF RV2626C ANTIGEN FOR DEVELOPING VACCINES AGAINST LATENT TUBERCULOSIS

MARÍA PAULA MORELLI; NICOLÁS O. AMIANO; CASTELLO, FLORENCIA; JOAQUIN M. PELLEGRINI; NANCY TATEOSIAN; LILIANA CUSMANO; CLAUDIO GALLEGO; DOMINGO PALMERO; MARIA PAULA DEL MEDICO ZAJAC; GABRIELA CALAMANTE; MARIA MAGDALENA GHERARDI; VERÓNICA E. GARCIA

Mar del Plata

Congreso; LXIII Reunión Científica Anual de la Sociedad Argentina de Investigaciones Clinicas (SAIC), LXVI Reunión Anual de la Sociedad Argentina de Inmunología (SAI); 2018

SAIC-SAI-SAFIS

Tuberculosis is one of the most prevalent infectious diseases. Nearly1/3 of the world population is latently infected (LTBI) with Mycobacteriumtuberculosis (Mtb) and at risk of disease reactivation. Theaim of this work was to study the potential of Rv2626c, an antigensecreted by Mtb during LTBI, to develop therapeutic vaccines. Previously,we demonstrated that rRv2626c induced IFN-γ responsesin peripheral blood mononuclear cells (PBMCs) from LTBI. In thiswork, we investigated the generation of polyfunctional responses(IFN-γ/IL-2/TNF-α) against Rv2626c. The results showed that 31%of responder CD4+LT produced more than one cytokine in LTBI aftertreatment with rRv2626c. However, only 19% of CD4+LT polyfunctionalcells were identified in Tuberculosis Patients (TB) and HealthyDonors (HD). Due to recent works have proposed that humoral immunityagainst Mtb might have a role in the defense against thepathogen, we decided to analyze the levels of IgG against Rv2626cin plasma from LTBI, TB and HD. We found that the levels of IgGsecreted by LTBI (42.29±12.39ng/ml) and TB (84.36±28.86 ng/ml)were higher as compared to HD (13.71±2.96ng/ml)(p